- Home
- CABA vs NPV Comparison
CABA vs NPV Comparison
Compare CABA & NPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- NPV
- Stock Information
- Founded
- CABA 2017
- NPV 1993
- Country
- CABA United States
- NPV United States
- Employees
- CABA N/A
- NPV N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- NPV Investment Managers
- Sector
- CABA Health Care
- NPV Finance
- Exchange
- CABA Nasdaq
- NPV Nasdaq
- Market Cap
- CABA 233.2M
- NPV 211.4M
- IPO Year
- CABA 2019
- NPV N/A
- Fundamental
- Price
- CABA $2.32
- NPV $11.33
- Analyst Decision
- CABA Strong Buy
- NPV
- Analyst Count
- CABA 8
- NPV 0
- Target Price
- CABA $13.50
- NPV N/A
- AVG Volume (30 Days)
- CABA 5.3M
- NPV 38.9K
- Earning Date
- CABA 11-10-2025
- NPV 01-01-0001
- Dividend Yield
- CABA N/A
- NPV 3.90%
- EPS Growth
- CABA N/A
- NPV N/A
- EPS
- CABA N/A
- NPV N/A
- Revenue
- CABA N/A
- NPV N/A
- Revenue This Year
- CABA N/A
- NPV N/A
- Revenue Next Year
- CABA N/A
- NPV N/A
- P/E Ratio
- CABA N/A
- NPV N/A
- Revenue Growth
- CABA N/A
- NPV N/A
- 52 Week Low
- CABA $0.99
- NPV $8.92
- 52 Week High
- CABA $5.46
- NPV $11.55
- Technical
- Relative Strength Index (RSI)
- CABA 44.66
- NPV 40.13
- Support Level
- CABA $2.30
- NPV $11.32
- Resistance Level
- CABA $2.67
- NPV $11.48
- Average True Range (ATR)
- CABA 0.33
- NPV 0.11
- MACD
- CABA -0.07
- NPV -0.01
- Stochastic Oscillator
- CABA 8.05
- NPV 3.72
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. Company mostly invest in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities , Housing/Multifamily, Transportation, and Others.